Compare Immunovant Inc. Common Stock (IMVT) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Visa Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Visa Inc trades at $375.1 (market cap $704.20B). The key difference: Visa Inc is far larger — about 106.4× Immunovant Inc. Common Stock's market cap, and Visa Inc pays a 0.71% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Visa Inc for 115 Days on average.
| IMVT | V | |
|---|---|---|
Market Cap | $6.62B | $704.20B |
Volume | 1,131,364 | 6,405,857 |
Sector | Health | Financials |
52-Week High | $44.96 | $384.14 |
52-Week Low | $17.03 | $295.52 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $5.72B | $714.78B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Visa (V) trades at $372.10, up 0.39% with a bullish technical outlook. The stock shows strong fundamentals with 85% analyst buy ratings and a $422.24 consensus price target, representing 13.5% upside. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $3.32 exceeding the $3.23 forecast. The company maintains exceptional profitability with 50.78% net margins and 61.79% ROE, while expanding AI-driven commerce initiatives through new partnerships and technology platforms.
Visa presents a compelling long-term investment case with dominant market position, consistent earnings growth, and strategic AI integration. Key risks include regulatory pressures, fintech competition, and stablecoin disruption potential. The current valuation at 31.67x P/E reflects premium pricing but is supported by strong growth prospects and defensive cash flow characteristics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
